NewVale Capital Closes $167 Million Inaugural Fund to Accelerate Growth of Pharmaceutical Services Companies

NewVale Capital LLC, a growth equity firm based in Boulder, has successfully closed its inaugural fund at $167 million. The firm focuses on investments in the infrastructure of the life science industry, particularly in revenue-generating services businesses essential for delivering medicines to patients.

NewVale's investments target services, software, and technologies that provide a proven return on investment for pharmaceutical customers, aiming to accelerate timelines, reduce costs, and enhance quality. With almost $200 million in total under management, the firm makes investments ranging from $10 million to $50 million in growth companies across the pharmaceutical value chain.

The NewVale team consists of experienced life science investors, company builders, and pharmaceutical executives. The fund has already completed three initial investments and has garnered significant support from institutional limited partners and pharmaceutical industry players.

NewVale Capital was founded in 2022 and focuses on supporting services businesses across the life science ecosystem. For more information, visit here.